Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Sold by American Century Companies Inc.

American Century Companies Inc. reduced its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 54.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,198 shares of the biotechnology company’s stock after selling 47,511 shares during the period. American Century Companies Inc.’s holdings in Aldeyra Therapeutics were worth $196,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ALDX. Catalyst Funds Management Pty Ltd grew its holdings in Aldeyra Therapeutics by 2,083.3% in the fourth quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 12,500 shares during the last quarter. U.S. Capital Wealth Advisors LLC acquired a new stake in Aldeyra Therapeutics in the 4th quarter valued at about $69,000. BNP Paribas Financial Markets increased its holdings in Aldeyra Therapeutics by 253.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 14,229 shares of the biotechnology company’s stock valued at $77,000 after acquiring an additional 10,201 shares in the last quarter. Captrust Financial Advisors raised its position in Aldeyra Therapeutics by 89.3% during the third quarter. Captrust Financial Advisors now owns 19,261 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 9,087 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in Aldeyra Therapeutics by 14.4% during the fourth quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 2,822 shares during the last quarter. 59.71% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of Aldeyra Therapeutics stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total value of $4,828,000.00. Following the transaction, the insider now owns 5,875,851 shares in the company, valued at $8,343,708.42. This trade represents a 36.65 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 8.50% of the company’s stock.

Wall Street Analyst Weigh In

ALDX has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research report on Friday, April 4th. BTIG Research dropped their price target on Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, April 7th.

Aldeyra Therapeutics Stock Performance

Shares of ALDX opened at $2.12 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. Aldeyra Therapeutics, Inc has a 1 year low of $1.14 and a 1 year high of $7.20. The company’s 50 day simple moving average is $5.46 and its 200 day simple moving average is $5.24.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.30). As a group, research analysts forecast that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.